GSK3B and mood disorder: Glycogen synthase kinase 3β (GSK3β) has been shown to be relevant in the pathophysiology of mood disorders; GSK3β inhibitors may reduce neuroinflammation and are essential for strengthening CREB activity (Pláteník et al., 2014).